Skip Navigation

DRUG RECORD

 

DIPHENOXYLATE

OVERVIEW
Diphenoxylate

 

Introduction

Diphenoxylate is synthetic opioid that primarily affects opiate receptors in the intestine and is used to treat diarrhea.  Diphenoxylate has not been linked to serum enzyme elevations during therapy or to clinically apparent liver injury.

 

Background

Diphenoxylate (dye” fen ox’ i late) is a synthetic piperidine derivative that acts as a mild opiate receptor agonist (predominant µ type receptors), but is used largely for the treatment of diarrhea rather than pain.  Diphenoxylate is similar to loperamide and is not structurally related to morphine or codeine, and has minimal euphoric or analgesic effects, largely because it is given in low doses and in fixed combination with atropine.  Diphenoxylate acts as a potent opiate agonist in the intestine and reduces intestinal motility, causing a slowing of intestinal transport and increased resorption of water and electrolytes, actions that are helpful in treating diarrhea.  Typically, low doses of atropine are added to diphenoxylate to prevent abuse and excessive intake.  Diphenoxylate in combination with atropine was approved for use in the United States in 1960 and is still widely used to treat acute infectious and nonspecific diarrhea caused by gastroenteritis.  Diphenoxylate with atropine is available as tablets 2.5 mg of diphenoxylate with 0.025 mg of atropine and as a solution of similar concentration in 5 mL generically and under the brand name Lomotil.  The usual dose in adults is 5 mg four times a day for until diarrhea is controlled, followed by 2.5 mg up to four times daily as needed.  Chronic therapy is not recommended.  Side effects of diphenoxylate include abdominal bloating and pain, nausea and vomiting and constipation.  Because there is systemic absorption, diphenoxylate can also cause central nervous system opioid effects such as confusion, drowsiness, euphoria, dizziness, headache, and respiratory depression.  Rare side effects include hypersensitivity reactions, pancreatitis and paralytic ileus.  Diphenoxylate with atropine is classified as a controlled substance schedule V, indicating that it has a minimal potential for abuse.  Diphenoxylate is available by prescription only.

 

Hepatotoxicity

As with most opiates in current use, therapy with diphenoxylate with atropine has not been linked to serum enzyme elevations.  There have been no convincing cases of idiosyncratic acute, clinically apparent liver injury attributed to diphenoxylate.  The reason for its lack of hepatotoxicity may relate partially to the low doses used.  What diphenoxylate that is absorbed is metabolized in the liver.

References on the safety and potential hepatotoxicity of diphenoxylate are given in the Overview section of the Opioids.

 

Drug Class:  Gastrointestinal Agents; Opioids

 

Top of page


PRODUCT INFORMATION
Diphenoxylate

 

REPRESENTATIVE TRADE NAMES
Diphenoxylate (with Atropine) – Generic, Lomotil®

 

DRUG CLASS
Gastrointestinal Agents; Opioids

 

COMPLETE LABELING

Product labeling at DailyMed, National Library of Medicine, NIH

 

Top of page


DRUG CAS REGISTRY NO. MOLECULAR FORMULA STRUCTURE
Diphenoxylate 915-30-0 C30-H32-N2-O2 Diphenoxylate Chemical Structure

Top of page


OTHER REFERENCE LINKS
Diphenoxylate
  1. PubMed logoRecent References on Diphenoxylate

  2. Clinical Trials logoTrials on Diphenoxylate

Top of page